Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aeglea Bio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AGLE
Nasdaq
8731
https://www.aeglea.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aeglea Bio Therapeutics Inc
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
- Jun 13th, 2022 4:01 pm
Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is not what insiders may have expected
- Jun 9th, 2022 1:56 pm
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
- Jun 3rd, 2022 2:49 pm
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
- Jun 2nd, 2022 7:26 pm
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
- Jun 2nd, 2022 7:20 pm
Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy
- Jun 2nd, 2022 4:09 pm
Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug
- Jun 2nd, 2022 3:24 pm
Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
- Jun 2nd, 2022 12:59 pm
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
- Jun 1st, 2022 6:25 pm
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
- Jun 1st, 2022 6:22 pm
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
- May 31st, 2022 3:26 pm
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
- May 26th, 2022 3:18 pm
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
- May 25th, 2022 4:07 pm
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
- May 23rd, 2022 3:46 pm
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
- May 23rd, 2022 3:33 pm
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
- May 20th, 2022 1:50 pm
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
- May 18th, 2022 3:47 pm
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
- May 18th, 2022 3:03 pm
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
- May 17th, 2022 3:31 pm
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
- May 13th, 2022 2:30 pm
Scroll